Japan To Speed Approval Process For Academically Developed Drugs
This article was originally published in PharmAsia News
Academically developed drugs are to get faster reviews in Japan under a regulatory change to become effective as early as fiscal 2014.
You may also be interested in...
The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.
A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.
The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.